2 completed, 1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow SAR-CoV-2: new trials by email Literature Review of SAR-CoV-2 trials Research Report on SAR-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) Baloxavir, Placebo Control - Influenza A, Influenza B | Phase 3 | Recruiting | Unity Health Toronto | 264 | 2026-04-29 | 2026-08-18 |
| Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection Evaluation of the T cell response in terms of IFN-γ measured by ELISpot - SAR-CoV-2, Cellular Immune Response | Completed | IRCCS San Raffaele | 127 | 2022-06-28 | 2025-07-14 | |
| Long-term Effects of COVID-19 (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195), 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB) - COVID-19, SAR-CoV-2 | Completed | Mayo Clinic | 71 | 2022-01-19 | 2025-02-07 |
COVID-19 (2) · Influenza, Human (1) · Respiratory Tract Infections (1)
Coronaviridae Infections (2) · Coronavirus Infections (2) · Infections (2) · Lung Diseases (2) · Nidovirales Infections (2) · Pneumonia (2) · Pneumonia, Viral (2) · RNA Virus Infections (2) · Respiratory Tract Diseases (2) · Virus Diseases (2) · Orthomyxoviridae Infections (1) · Respiratory Tract Infections (1)
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · PK 11195 (1) · baloxavir (1)
IRCCS San Raffaele (1) · Mayo Clinic (1) · Unity Health Toronto (1)
Canada (1) · Italy (1) · United States (1)
Andrew Pinto, MD (1) · Patrizia Rovere Querini, PhD, MD (1) · Young Erben, MD (1)
R35NS097273 (1)